PMCB Stock, SGOC Stock, VRPX Stock, WTER Stock, AQST Stock, SOS Limited Stock, ENVB Stock UPDATE

#amc #wallstreetbets #stockmarkettoday
MAKE SURE YOU JOIN OUR 🔥NEW🔥 DISCORD

ITS CALLED MAKING EASY MONEY link below👇👇
https://discord.gg/4WyYRrSd

Virpax Pharmaceuticals Inc (NASDAQ:VRPX) is surging higher Tuesday after the company announced that it received a written pre-investigational new drug response from the U.S. Food and Drug Administration for MMS019.

MMS019 is Virpax Pharmaceuticals patented and proprietary high-density molecular masking spray under development for use as an anti-viral barrier product.
NanoVibronix Inc (NASDAQ:NAOV) plans to enter the Over-the-Counter (OTC) pain relief market by introducing PainShield RELIEF, a non-prescription ultrasound therapy device.
Brian Murphy, Chief Executive Officer, commented, "Entering the OTC pain relief market with our newest product in the PainShield family significantly expands our total addressable market and opens up new opportunities for growth through several additional revenue streams."
NanoVibronix plans to target specific pain relief indications and the retail channels to address them as an OTC alternative to less effective interventions.
Cara is developing KORSUVA, an anti-itch drug with a variety of applications. It is currently the only drug candidate in the company’s development platform, but it is being tested in relation to itching in a variety of health conditions.

The leading indication in the KORSUVA pipeline is its program researching efficacy with CKD-HD related pruritis – that’s itchiness caused by chronic kidney problems. This pathway has completed its clinical trials, and the New Drug Application (NDA) has been sent to the FDA. The scheduled decision date is this coming August 23.